SCHEMBL6475815

SCHEMBL6475815

CCC(=O)c1ccc(OS(=O)(=O)C(F)(F)F)c(CC)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
SMN1; SMN2 Q16637 3/20 0.41
HPGD P15428 2/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 2/20 0.39
HTT P42858 1/20 0.39
PLA2G2D Q9UNK4 1/20 0.38
PPARG P37231 2/20 0.37
PPARA Q07869 2/20 0.37
MAPT P10636 3/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
DRD2 P14416 1/20 0.37
DRD1 P21728 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1023633 0.91 PPARG (0.46) MEN1KMT2ASMN1; SMN2HPGDNPC1
SCHEMBL3817347 0.85 MEN1 (0.59) MEN1KMT2ASMN1; SMN2HPGDNPC1
SCHEMBL6472219 0.83 MEN1 (0.41) MEN1KMT2ASMN1; SMN2HPGDNPC1
SCHEMBL13678676 0.78 KDM4E (0.43) KMT2ASMN1; SMN2KDM4EDRD2DRD1
SCHEMBL6511762 0.77 DRD2 (0.39) MEN1KMT2ASMN1; SMN2KDM4EALDH1A1
SCHEMBL28334586 0.77 SLC6A2 (0.40) MAPTL3MBTL1DRD2DRD1DRD4
SCHEMBL36007 0.76 PPARG (0.43) MEN1KMT2ASMN1; SMN2HPGDNPC1
SCHEMBL14421954 0.76 NPC1 (0.47) MEN1KMT2ASMN1; SMN2HPGDNPC1
SCHEMBL9123311 0.75 CYP4F2 (0.38) KMT2ASMN1; SMN2HPGDNPC1L3MBTL1
SCHEMBL22032224 0.74 ALDH1A1 (0.40) MEN1KMT2AHPGDALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-100376530-C Vitamin D analogues GALDERMA RES & DEV (FR) 2008-03-26 CN disclosed
US-6924400-B2 Triaromatic vitamin D analogues GALDERMA RESEARCH & DEVELOPMENT, SNC (FR) 2005-08-02 US disclosed
CN-1620414-A Vitamin D analogues GALDERMA RES & DEV (FR) 2005-05-25 CN disclosed
US-20030195259-A1 Triaromatic vitamin D analogues GALDERMA RESEARCH & DEVELOPMENT (FR) 2003-10-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030195259-A1 Triaromatic vitamin D analogues CYP24A1, CYP2R1, VDR MEN1 945/4885KMT2A 4353/4885SMN1; SMN2 4849/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.